2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

cytotoxic T and natural killer cells

" in MedChemExpress (MCE) Product Catalog:

4

Inhibitors & Agonists

3

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-160421
    TREM2-IN-1

    		Apoptosis Inflammation/Immunology Cancer
    TREM2-IN-1 (OPA) is a TREM2 inhibitor derived from oxaliplatin and artesunate. TREM2-IN-1 can relieves immunosuppressive tumor microenvironment and enhancing chemical anticancer efficiency. TREM2-IN-1 deters the tumor growth in mice models bearing MC38 colorectal tumor by reducing the number of CD206 + and CX3CR1 + immunosuppressive macrophages. TREM2-IN-1 also promotes the expansion and infiltration of immunostimulatory dendritic, cytotoxic T and natural killer cells .
    TREM2-IN-1
  • HY-P99055
    Urelumab

    		TNF Receptor Inflammation/Immunology Cancer
    Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
    Urelumab
  • HY-P991214
    Tucotuzumab celmoleukin

    EMD 273066; huKS-IL2

    		 Interleukin Related Cancer
    Tucotuzumab celmoleukin (EMD 273066) is an immunocytokine fusion agent targeting the epithelial cell adhesion molecule (EpCAM). Tucotuzumab celmoleukin binds to EpCAM and delivers IL-2 to the tumor microenvironment, which can activate cytotoxic effector cells, such as CD8+ T cells and natural killer (NK) cells. Tucotuzumab celmoleukin is promising for research of EpCAM-positive cancers, such as colorectal cancer and prostate cancer .
    Tucotuzumab celmoleukin
  • HY-P991530
    YH004

    		Biochemical Assay Reagents Inflammation/Immunology Cancer
    YH004 is an anti-CD137 agonistic monoclonal antibody, with immunostimulating and antineoplastic activities. YH004 activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer cells. YH004 enhances CD137-mediated signaling and induces cytotoxic T-lymphocyte (CTL) proliferation, cytokine production and promotes anti-tumor response mediated by CTL. YH004 induces NK-mediated tumor cell killing and suppresses the immunosuppressive activity of regulatory T cells. YH004 can be studied in anticancer research .
    YH004

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: